Compare TUSK & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TUSK | ENTX |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.3M | 147.4M |
| IPO Year | 2016 | 2015 |
| Metric | TUSK | ENTX |
|---|---|---|
| Price | $3.16 | $2.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 102.0K | ★ 358.0K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 102.32 | N/A |
| EPS | 0.09 | ★ 0.22 |
| Revenue | ★ $44,292,000.00 | $42,000.00 |
| Revenue This Year | $383.90 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.78 | ★ $13.77 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.72 | $0.91 |
| 52 Week High | $3.92 | $4.20 |
| Indicator | TUSK | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 50.47 |
| Support Level | $2.98 | $2.73 |
| Resistance Level | $3.32 | $3.10 |
| Average True Range (ATR) | 0.12 | 0.19 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 65.67 | 48.94 |
Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes rental services, infrastructure services, natural sand proppant services, accommodation services, and drilling services.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.